<DOC>
	<DOCNO>NCT03064113</DOCNO>
	<brief_summary>Thirty-two subject diagnose COPD enrol , receive study treatment complete follow-up assessment . During four study period , subject admit clinic Day -1 house overnight last spirometry measurement . Serial pulmonary function test perform PK ( pharmacokinetics ) sample collect 25 hour . Subjects discharge clinic Day 2 evaluation .</brief_summary>
	<brief_title>Effects TD-4208 FEV1 Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Subjects assign one 4-treatment sequence group present table accord randomization schedule supply Sponsor study initiation . The randomization scheme include assignment replacement subject . Subjects report respective clinical research unit ( CRU ) Admission/Day −1 pre-randomization procedure confirmation eligibility ( continued eligibility Periods 2 4 ) . The unblinded pharmacist prepare dispensed nebulizer , accord randomization schedule 4 period . Dosing occur morning , generally 7 9 . For Periods 2 4 , dose occur within ±30 minute dose time establish Period 1 . Study drug administer respective CRU supervision study personnel . Single dose TD-4208 , ipratropium bromide , placebo administer clinical research unit ( CRU ) supervision study personnel . Care take avoid eye contact study drug . Residual drug solution remain nebulizer ( ie , mL ) measure record . The investigator designee responsible maintain accountability record study drug ( ) accordance applicable government regulation study procedure . The accountability record include entry receipt , distribution dispensing , destruction material ( ) . Unused expire study drug dispose accordance write instruction Sponsor .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Diagnosis moderate stable Chronic Obstructive Pulmonary . Disease FEV1/FVC &lt; 0.7 screening . Woman nonchildbearing potential . Female participant childbearing potential must test negative pregnancy must use highly effective method birth control study least 1 month completion study dose . Female participant must breastfeed . Men must agree use highly effective method birth control partner childbearing potential study 1 month completion study dose . Current past smoke history &gt; 10 packyears . Must capable perform reproducible spirometry maneuver . History significant respiratory disease COPD , and/ require daily longterm oxygen therapy . Exacerbation COPD , lung infection within 6 week prior study . Start change dose COPD treatment 4 week study . Daily use maintenance systemic/inhaled corticosteroid ( &gt; 1000 microgram fluticasone propionate equivalent &gt; 5 mg prednisone ) . Use bronchodilator medication treatment COPD , aspirin , antiinflammatories specific time , prior first dose willing abstain use specify time period prior study dose administration . Symptomatic prostrate hypertrophy , bladder neck obstruction , active cancer , narrow angle glaucoma . Clinical significant hypersensitivity medication . Participants uncontrolled hematologic , immunologic , renal , neurologic , hepatic , endocrine disease may place participant risk . Cerebrovascular , cardiovascular disease abnormal ECG . History drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease , COPD</keyword>
</DOC>